Acme United Q2 2026 Earnings: EPS and Revenue Beat on MyMedic Acquisition and Margin Expansion

• Acme United reported a significant Q2 2026 beat on both EPS ($1.22 vs. $0.81 est.) and revenue ($62.7M vs. $58.1M est.) .
• The growth was primarily fueled by the integration of the MyMedic acquisition, alongside 8% organic growth .
• Gross margins expanded to 42.6%, with management citing easing tariff pressures as a key driver for continued profitability .
• The stock surged approximately 11.92% following the report, approaching its 52-week high of $51.88 .

Acme United Corporation (ACU) delivered strong second-quarter 2026 results, significantly exceeding analyst expectations across the board. Earnings per share reached $1.22 on a diluted basis against a forecast of $0.81, representing a 50.62% positive surprise. Revenue also topped estimates at $62.7 million compared to the $58.1 million forecast, marking a 7.99% revenue surprise .

The stock responded enthusiastically to the financial release, surging approximately 11.92% following the report. This movement brought the share price near a 52-week high of $51.88, reflecting strong investor confidence in the company's operational execution and strategic direction .

Looking ahead, management provided optimistic guidance for the remainder of the year. CEO Johnsen highlighted that margin recovery is expected to continue as tariff-related pressures ease. Specifically, the company is transitioning from higher-tariff inventory to lower-cost stock throughout the year-end period, which should further support margin expansion .

What Drives Acme United’s Q2 2026 Outperformance

The top-line growth was robust, rising 16% year-over-year. This increase was primarily attributed to the integration of the MyMedic acquisition, while organic growth stood at a solid 8% excluding acquisition effects . The dual engine of acquisition-led and organic growth provided a solid foundation for the quarter's financial success .

Profitability metrics improved notably, with gross margins expanding to 42.6% from 41.0% in the prior year period. This expansion indicates improved pricing power or cost efficiencies within the company's core operations . The margin improvement was a key driver for investor sentiment, as it demonstrated the company's ability to manage costs effectively .

Strategic focus remains on the MyMedic brand, with ongoing integration efforts aimed at expanding distribution beyond direct-to-consumer channels into mass retail markets. The company anticipates strong fourth-quarter profitability driven by seasonal demand patterns for their medical devices . This strategic shift is expected to unlock further value from the MyMedic acquisition in the coming quarters .

What Key Risks and Headwinds Could Impact Future Margins

Despite the strong Q2 performance, investors should monitor key risks that could impact future profitability. Selling, General, and Administrative (SG&A) expenses remain elevated at 32% of sales. These high operating costs could potentially compress net margins if not managed effectively .

Additionally, the company faces ongoing exposure to tariff and freight costs, currency headwinds, and uneven geographic performance. The Canadian market, in particular, is currently lagging behind other regions, which could dampen overall growth . These external factors require careful monitoring as they could offset the benefits of easing tariff pressures .

Currency volatility also presents a risk to the company's international operations. Fluctuations in exchange rates could impact the value of sales and costs in non-US markets, adding another layer of complexity to financial planning . Investors are closely watching how the company navigates these macroeconomic headwinds .

The integration of MyMedic is progressing, but challenges remain in expanding its distribution network. The transition from direct-to-consumer to mass retail requires significant investment and operational changes. Management is committed to this strategy, but execution risks remain .

Overall, Acme United's Q2 2026 results demonstrate strong operational performance and strategic progress. The company is well-positioned to capitalize on seasonal demand and margin expansion opportunities. However, investors should remain cautious of the identified risks and monitor the company's ability to manage them effectively .